G1 Therapeutics, Inc.
G1 Therapeutics, Inc.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Trilaciclib and Lurbinectidin | Cytopenia, Hemic and Lymphatic Diseases, Neoplasms by Site, Thoracic Neoplasms, agranulocytosis, bronchial neoplasm, bronchogenic carcinoma, hematologic disorder, leukocyte disorder, leukopenia, lung cancer, lung disorder, lung neoplasm, neoplasm, neutropenia, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 | 2026-09-21 | NCT05578326 | |
| Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-08-20 | NCT06027268 |